Truist Financial Sets $798 Price Target for Regeneron Pharmaceuticals
Truist Financial established a price target of $798 for Regeneron Pharmaceuticals (NASDAQ:REGN). The biotechnology company's stock showed resilience with a 1.71% increase.
The price target implies a potential increase from the company's current trading level. Regeneron Pharmaceuticals shares were trading at $768.79 on November 24, 2025. This represented a gain of $12.89, or 1.71%, from its prior closing price. The stock's intraday trading range was between $757 and $773.13.
Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of approximately $79.4 billion. The company's stock recorded a trading volume of 156,611 shares on the NASDAQ exchange.
In the past year, Regeneron's stock has fluctuated between a low of $476.49 and a high of $800.99. The broader market has experienced volatility, partly due to NVIDIA Corp's earnings report. Market participants are anticipating a period of reduced volatility during the upcoming shortened holiday week.
Regeneron Pharmaceuticals, Inc. (REGN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.